Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper 1 – Gastrointestinal tumours, non-colorectal

3502 - Randomised Efficacy and Safety Results For Atezolizumab (Atezo) + Bevacizumab (Bev) in Patients (pts) With Previously Untreated, Unresectable Hepatocellular Carcinoma (HCC)


27 Sep 2019


Proffered Paper 1 – Gastrointestinal tumours, non-colorectal


Tumour Site

Hepatobiliary Cancers


Michael Lee


Annals of Oncology (2019) 30 (suppl_5): v851-v934. 10.1093/annonc/mdz394


M. Lee1, B. Ryoo2, C. Hsu3, K. Numata4, S. Stein5, W. Verret6, S. Hack6, J. Spahn6, B. Liu7, H. Abdullah8, R. He9, K. Lee10

Author affiliations

  • 1 Unc Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, NC 27514 - Chapel Hill/US
  • 2 Dept. Of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 138-931 - Seoul/KR
  • 3 Department Of Oncology, National Taiwan University Hospital, 10002 - Taipei City/TW
  • 4 Department Of Gastroenterology, Yokohama City University Medical Center, Yokohama/JP
  • 5 Medical Oncology, Yale School of Medicine, New Haven/US
  • 6 Product Development - Oncology, Genentech, Inc., South San Francisco/US
  • 7 Biostatistics. Pdbb, Genentech, Inc., South San Francisco/US
  • 8 Safety Science Oncology, Genentech, Inc., South San Francisco/US
  • 9 Department Of Medicine, Georgetown University Medical Center, Washington/US
  • 10 Internal Medicine, Seoul National University Hospital, 110-744 - Seoul/KR


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3502


Pts with unresectable HCC have few treatment (tx) options. Checkpoint inhibitors and combination approaches with anti-VEGFs are emerging as potential new tx options. Here we report the first randomised dataset evaluating atezo (anti-PD-L1) as monotherapy vs the combination of atezo + bev (anti-VEGF; Arm F) as well as updated single-arm atezo + bev data (Arm A) from a Ph 1b study.


Arms F and A of the Ph 1b study GO30140 enrolled systemic tx-naïve pts with unresectable HCC. Arm F pts were randomised 1:1 to atezo + bev or atezo monotherapy and received atezo 1200 mg IV q3w, bev 15 mg/kg IV q3w until unacceptable toxicity or loss of clinical benefit. Arm A pts received atezo + bev. Primary endpoints were progression free survival (PFS; Arm F) and objective response rate (ORR, Arm A) by independent review facility (IRF)-assessed RECIST 1.1, and safety (Arms F and A).


In Arm F, 60 pts were randomised to atezo + bev (Group F1) and 59 pts to atezo (Group F2). Arm F showed a statistically significant improvement in the primary endpoint median PFS for atezo + bev vs atezo (5.6 vs 3.4 mo, HR 0.55, 80% CI, 0.40 – 0.74, P = 0.0108). Any-Gr TRAEs occurred in 41 (68%) F1 pts and 24 (41%) F2 pts; Gr 3-4 TRAEs occurred in 12 (20%) F1 pts and 3 (5%) F2 pts. There were no Gr 5 TRAEs in Arm F. For the 104 pts in Arm A, primary endpoint ORR was 36% (37 pts) with 76% ongoing. Any-Grade (Gr) tx-related adverse events (TRAEs) occurred in 91 (88%) pts; Gr 3-4 TRAEs occurred in 41 (39%) pts. Gr 5 TRAEs were seen in 3 (3%) pts.


By meeting its primary endpoint of improved PFS for atezo + bev vs atezo alone, Arm F showed the single-agent contribution of atezo and bev to the overall tx effect. With longer follow up, Arm A highlights the clinically meaningful and durable responses of atezo + bev. Coupled with a tolerable safety profile, these data suggest that atezo + bev is a promising first-line tx option for unresectable HCC.

Clinical trial identification


Editorial acknowledgement

Medical writing assistance was provided by Steffen Biechele, PhD, of Health Interactions and funded by F. Hoffmann-La Roche, Ltd.

Legal entity responsible for the study

F. Hoffmann-La Roche, Ltd.


F. Hoffmann-La Roche, Ltd.


M. Lee: Research grant / Funding (self): Amgen; Research grant / Funding (self): Bristol-Myers Squibb ; Research grant / Funding (self): Pfizer; Research grant / Funding (self): EMD Serono; Research grant / Funding (self): Genentech/Roche. C. Hsu: Honoraria (institution), Advisory / Consultancy: BMS; Honoraria (institution), Advisory / Consultancy: Ono Pharmaceutical; Honoraria (institution), Research grant / Funding (self): MSD; Advisory / Consultancy: Eli Lilly; Advisory / Consultancy: AZ; Advisory / Consultancy: Roche. S. Stein: Advisory / Consultancy: Genentech; Advisory / Consultancy: BMS; Advisory / Consultancy: Eisai; Advisory / Consultancy: Bayer; Advisory / Consultancy: Exelixis. W. Verret: Full / Part-time employment: Genentech/Roche. S. Hack: Shareholder / Stockholder / Stock options, Full / Part-time employment: Genentech/Roche. J. Spahn: Shareholder / Stockholder / Stock options, Full / Part-time employment: Genentech/Roche. B. Liu: Shareholder / Stockholder / Stock options, Full / Part-time employment: Genentech/Roche. H. Abdullah: Full / Part-time employment: Genentech/Roche. R. He: Speaker Bureau / Expert testimony: Bayer; Speaker Bureau / Expert testimony: BMS; Speaker Bureau / Expert testimony: Eisai Inc.; Speaker Bureau / Expert testimony: Exelixis Inc; Advisory / Consultancy, Research grant / Funding (institution): Merck & Co; Advisory / Consultancy: AZ. K. Lee: Honoraria (self), Speaker Bureau / Expert testimony: AstraZeneca; Honoraria (self): Bayer; Honoraria (self): Eisai; Honoraria (self): Ono Pharmaceuticals; Honoraria (self), Speaker Bureau / Expert testimony: Roche; Honoraria (self): Samsung Bioepis; Speaker Bureau / Expert testimony: Eli Lilly. All other authors have declared no conflicts of interest.Table:


Arm F
F1 Atezo + Bev (n = 60)F2 Atezo (n = 59)aF1 Atezo + Bev (n = 60)F2 Atezo (n = 59)a
Median follow-up, mo6.
Median PFS, mo 95% CI5.6b 3.6 – 7.43.4b 1.9 – 5.25.6 3.6 – 7.43.4 1.9 – 5.2
80% CI0.40 – 0.74 P = 0.01080.40 – 0.74
Arm A: Atezo + Bev
n = 104
Median follow-up, mo12.4
Confirmed ORR, n (%)37 (36)b41 (39)
95% CI (%)26 – 4630 – 50
Complete Response (CR), n (%)12 (12)16 (15)
Partial Response (PR), n (%)25 (24)25 (24)
On-going response, n (%)28 (76)28 (68)
DCR (CR + PR + SD), n (%)74 (71)74 (71)
Median DOR, moNENE
95% CI11.8 – NE11.8 – NE
Median PFS, mo7.37.3
95% CI5.4 – 9.95.4 – 9.9

DCR, disease control rate; DOR, duration of response; NE, not estimable; SD, stable disease. Data cut off: 14 June 2019.


1 randomised pt did not receive atezo.


Primary endpoint.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.